Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group

Michael W. DeGregorio, Bert L. Lum, Walter M. Holleran, Bruce J. Wilbur, Branimir I. Sikic

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The pharmacokinetic behavior of carboplatin administered by the i.p. route at a dose of 200 mg/m2 was studied during five courses of therapy in four patients with ovarian cancer. A regional pharmacologic advantage was noted with carboplatin administered by this route, with (1) peak peritoneal fluid concentrations 18-fold those in plasma, and (2) area under the curve (AUC) for the peritoneum showing a 18-fold and 6-fold increase over plasma AUC at 4 and 24 h, respectively. The mean residence time of total platinum in the peritoneum was 4.7 h. Approximately 10% and 40% of plasma platinum was protein bound at 4 and 24 h after treatment, respectively, whereas peritoneal fluid platinum showed minimal protein binding. Peak plasma platinum levels were comparable to those recorded in previous studies with i.v. doses of carboplatin. Peritoneal clearance of carboplatin in these four patients appeared to be less than that previously reported for cisplatin. Further studies are in progress with higher doses of i.p. carboplatin.

Original languageEnglish (US)
Pages (from-to)235-238
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume18
Issue number3
DOIs
StatePublished - Dec 1986

Fingerprint

Pharmacokinetics
Oncology
Carboplatin
Platinum
Plasmas
Ascitic Fluid
Peritoneum
Area Under Curve
Fluids
Protein Binding
Ovarian Neoplasms
Cisplatin
Therapeutics
Proteins

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. / DeGregorio, Michael W.; Lum, Bert L.; Holleran, Walter M.; Wilbur, Bruce J.; Sikic, Branimir I.

In: Cancer Chemotherapy and Pharmacology, Vol. 18, No. 3, 12.1986, p. 235-238.

Research output: Contribution to journalArticle

DeGregorio, Michael W. ; Lum, Bert L. ; Holleran, Walter M. ; Wilbur, Bruce J. ; Sikic, Branimir I. / Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. In: Cancer Chemotherapy and Pharmacology. 1986 ; Vol. 18, No. 3. pp. 235-238.
@article{3cdd64a992874f7b959324e79e3d769f,
title = "Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group",
abstract = "The pharmacokinetic behavior of carboplatin administered by the i.p. route at a dose of 200 mg/m2 was studied during five courses of therapy in four patients with ovarian cancer. A regional pharmacologic advantage was noted with carboplatin administered by this route, with (1) peak peritoneal fluid concentrations 18-fold those in plasma, and (2) area under the curve (AUC) for the peritoneum showing a 18-fold and 6-fold increase over plasma AUC at 4 and 24 h, respectively. The mean residence time of total platinum in the peritoneum was 4.7 h. Approximately 10{\%} and 40{\%} of plasma platinum was protein bound at 4 and 24 h after treatment, respectively, whereas peritoneal fluid platinum showed minimal protein binding. Peak plasma platinum levels were comparable to those recorded in previous studies with i.v. doses of carboplatin. Peritoneal clearance of carboplatin in these four patients appeared to be less than that previously reported for cisplatin. Further studies are in progress with higher doses of i.p. carboplatin.",
author = "DeGregorio, {Michael W.} and Lum, {Bert L.} and Holleran, {Walter M.} and Wilbur, {Bruce J.} and Sikic, {Branimir I.}",
year = "1986",
month = "12",
doi = "10.1007/BF00273393",
language = "English (US)",
volume = "18",
pages = "235--238",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group

AU - DeGregorio, Michael W.

AU - Lum, Bert L.

AU - Holleran, Walter M.

AU - Wilbur, Bruce J.

AU - Sikic, Branimir I.

PY - 1986/12

Y1 - 1986/12

N2 - The pharmacokinetic behavior of carboplatin administered by the i.p. route at a dose of 200 mg/m2 was studied during five courses of therapy in four patients with ovarian cancer. A regional pharmacologic advantage was noted with carboplatin administered by this route, with (1) peak peritoneal fluid concentrations 18-fold those in plasma, and (2) area under the curve (AUC) for the peritoneum showing a 18-fold and 6-fold increase over plasma AUC at 4 and 24 h, respectively. The mean residence time of total platinum in the peritoneum was 4.7 h. Approximately 10% and 40% of plasma platinum was protein bound at 4 and 24 h after treatment, respectively, whereas peritoneal fluid platinum showed minimal protein binding. Peak plasma platinum levels were comparable to those recorded in previous studies with i.v. doses of carboplatin. Peritoneal clearance of carboplatin in these four patients appeared to be less than that previously reported for cisplatin. Further studies are in progress with higher doses of i.p. carboplatin.

AB - The pharmacokinetic behavior of carboplatin administered by the i.p. route at a dose of 200 mg/m2 was studied during five courses of therapy in four patients with ovarian cancer. A regional pharmacologic advantage was noted with carboplatin administered by this route, with (1) peak peritoneal fluid concentrations 18-fold those in plasma, and (2) area under the curve (AUC) for the peritoneum showing a 18-fold and 6-fold increase over plasma AUC at 4 and 24 h, respectively. The mean residence time of total platinum in the peritoneum was 4.7 h. Approximately 10% and 40% of plasma platinum was protein bound at 4 and 24 h after treatment, respectively, whereas peritoneal fluid platinum showed minimal protein binding. Peak plasma platinum levels were comparable to those recorded in previous studies with i.v. doses of carboplatin. Peritoneal clearance of carboplatin in these four patients appeared to be less than that previously reported for cisplatin. Further studies are in progress with higher doses of i.p. carboplatin.

UR - http://www.scopus.com/inward/record.url?scp=0022871492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022871492&partnerID=8YFLogxK

U2 - 10.1007/BF00273393

DO - 10.1007/BF00273393

M3 - Article

VL - 18

SP - 235

EP - 238

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -